Louie Fidaxomicin
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 629 patients with Clostridium difficile infection, fidaxomicin reduced recurrence at 4 weeks compared with oral vancomycin with similar clinical cure.
N
629
Design
Double-blind RCT
Endpunkt
Clinical cure and recurrence
Relevanz
2
ErgebnisCure similar (~88 %); recurrence 15.4 % vs 25.3 % — fewer with fidaxomicin in non-NAP1 strains.
Louie TJ, et al. N Engl J Med. 2011;364(5):422-431. 10.1056/NEJMoa0910812
Diskussion & Kritik
Established fidaxomicin as the preferred agent for initial and first-recurrence CDI — now reflected in IDSA/SHEA 2021 guidance.